Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemia　― A Post-Marketing Survey (J-POSSIBLE) ―

Coronary lesion complexity in patients with heterozygous familial hypercholesterolemia hospitalized for acute myocardial infarction: data from the RICO survey

(2021) Hermann Yao et al.   Lipids in Health and Disease

Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association

(2021) Gissette Reyes-Soffer et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Familial Hypercholesterolemia in Patients with Acute Coronary Syndrome: Genetic Insights from EXPLORE-J

(2021) Mariko Harada-Shiba et al.   Journal of Atherosclerosis and Thrombosis

The Prevalence and Diagnostic Ratio of Familial Hypercholesterolemia (FH) and Proportion of Acute Coronary Syndrome in Japanese FH Patients in a Healthcare Record Database Study

(2020) Tamio Teramoto et al.   Cardiovascular Therapeutics

Treatment Patterns and Lipid Profile in Patients with Familial Hypercholesterolemia in Japan

(2018) Tamio Teramoto et al.   Journal of Atherosclerosis and Thrombosis

Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: Results of the EXPLORE-J study

(2018) Mariko Harada-Shiba et al.   ATHEROSCLEROSIS

Application of the Japanese Guidelines for the Diagnosis of Familial Hypercholesterolemia in General Practice: It is to be Validated in International Harmonization

(2018) Nobukiyo Tanaka et al.   Journal of Atherosclerosis and Thrombosis

Efficacy and safety of alirocumab 150 mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON

(2018) Tamio Teramoto et al.   Journal of Cardiology

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipid Lowering Therapy and Circulating PCSK9 Concentration

(2017) Tsuyoshi Nozue   Journal of Atherosclerosis and Thrombosis

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins　– ODYSSEY JAPAN Randomized Controlled Trial –

(2016) Tamio Teramoto et al.   CIRCULATION JOURNAL

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Familial Hypercholesterolemia: An Under-recognized but Significant Concern in Cardiology Practice

(2013) JoAnne M. Foody   CLINICAL CARDIOLOGY

Guidelines for the Management of Familial Hypercholesterolemia

(2012) Mariko Harada-Shiba et al.   Journal of Atherosclerosis and Thrombosis